Avacta Group PLC (AVCT) - Total Liabilities

Latest as of June 2025: GBX29.09 Million GBX ≈ $3.54K USD

Based on the latest financial reports, Avacta Group PLC (AVCT) has total liabilities worth GBX29.09 Million GBX (≈ $3.54K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Avacta Group PLC to track the company's year-over-year net asset growth rate.

Avacta Group PLC - Total Liabilities Trend (2001–2024)

This chart illustrates how Avacta Group PLC's total liabilities have evolved over time, based on quarterly financial data.

Avacta Group PLC Competitors by Total Liabilities

The table below lists competitors of Avacta Group PLC ranked by their total liabilities.

Company Country Total Liabilities
2CUREX AB SEK-10
F:2QE
Germany €4.55 Million
Xamble Group Ltd
AU:XGL
Australia AU$3.45 Million
IPB Petroleum Ltd
AU:IPB
Australia AU$57.33K
California Software Company Limited
NSE:CALSOFT
India Rs83.04 Million
Mare Nostrum
PA:ALMAR
France €80.01 Million
MANTLE MINERALS
F:MXB0
Germany €871.45K
Shamaym Improve Ltd
TA:SHMM
Israel ILA803.40K

Liability Composition Analysis (2001–2024)

This chart breaks down Avacta Group PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Avacta Group PLC stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.79 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 202.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.00 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Avacta Group PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Avacta Group PLC (2001–2024)

The table below shows the annual total liabilities of Avacta Group PLC from 2001 to 2024.

Year Total Liabilities Change
2024-12-31 GBX38.99 Million
≈ $4.74K
-24.13%
2023-12-31 GBX51.39 Million
≈ $6.25K
-30.76%
2022-12-31 GBX74.21 Million
≈ $9.03K
+1183.93%
2021-12-31 GBX5.78 Million
≈ $703.26
+4.46%
2020-12-31 GBX5.53 Million
≈ $673.21
+112.73%
2019-12-31 GBX2.60 Million
≈ $316.47
+27.50%
2018-07-31 GBX2.04 Million
≈ $248.21
+22.60%
2017-07-31 GBX1.66 Million
≈ $202.46
-1.94%
2016-07-31 GBX1.70 Million
≈ $206.48
-25.24%
2015-07-31 GBX2.27 Million
≈ $276.19
+2.62%
2014-07-31 GBX2.21 Million
≈ $269.14
+5.18%
2013-07-31 GBX2.10 Million
≈ $255.87
+37.27%
2012-07-31 GBX1.53 Million
≈ $186.40
+70.41%
2011-07-31 GBX899.00K
≈ $109.38
-28.19%
2010-07-31 GBX1.25 Million
≈ $152.33
+65.17%
2009-07-31 GBX758.00K
≈ $92.23
+175.64%
2008-07-31 GBX275.00K
≈ $33.46
+27.31%
2007-07-31 GBX216.00K
≈ $26.28
+1036.84%
2006-04-30 GBX19.00K
≈ $2.31
-90.21%
2005-04-30 GBX194.00K
≈ $23.60
-44.25%
2004-04-30 GBX348.00K
≈ $42.34
-15.53%
2003-04-30 GBX412.00K
≈ $50.13
-41.81%
2002-04-30 GBX708.00K
≈ $86.14
+23.13%
2001-04-30 GBX575.00K
≈ $69.96
--

About Avacta Group PLC

LSE:AVCT UK Biotechnology
Market Cap
$3.62 Million
GBX29.76 Billion GBX
Market Cap Rank
#29131 Global
#549 in UK
Share Price
GBX68.00
Change (1 day)
-0.73%
52-Week Range
GBX43.25 - GBX89.00
All Time High
GBX274.91
About

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more